Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: A phase II study Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Biomarkers
  • Carcinoma, Hepatocellular
  • Indoles
  • Liver Neoplasms
  • Pyrroles

abstract

  • Sunitinib shows evidence of modest antitumor activity in advanced HCC with manageable adverse effects. Rapid changes in tumor vascular permeability and circulating inflammatory biomarkers are potential determinants of response and resistance to sunitinib in HCC. Our study suggests that control of inflammation might be critical for improving treatment outcome in advanced HCC.

publication date

  • June 20, 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC2702235

Digital Object Identifier (DOI)

  • 10.1200/JCO.2008.20.9908

PubMed ID

  • 19470923

Additional Document Info

start page

  • 3027

end page

  • 35

volume

  • 27

number

  • 18